Sanguine Corporation SERVICE AGREEMENT THIS SERVICES AGREEMENT is effective as of the latest signature date by and between IriSys Research and Development LLC (hereinafter "Contractor"), with its principal place of business at 6190 Cornerstone Court...Service Agreement • February 22nd, 2001 • Sanguine Corp • In vitro & in vivo diagnostic substances • California
SUBSCRIPTION AGREEMENT FOR PROSPECTIVE SUBSCRIBERS OF UNITS SANGUINE CORPORATIONSubscription Agreement • September 15th, 2000 • Sanguine Corp • In vitro & in vivo diagnostic substances
APRIL 2000 CONSULTANT COMPENSATION AGREEMENT THIS CONSULTANT COMPENSATION AGREEMENT (the "Plan") is made this 5th day of May, 2000, among Sanguine Corporation, a Nevada corporation ("Sanguine"); and Karl Smith, David E. Nelson, Leonard W. Burningham,...Consultant Compensation Agreement • May 9th, 2000 • Sanguine Corp • In vitro & in vivo diagnostic substances • Nevada
FINANCIAL CONSULTING SERVICES AGREEMENTFinancial Consulting Services Agreement • December 17th, 2001 • Sanguine Corp • In vitro & in vivo diagnostic substances • California
December 11, 2001 Leonard W. Burningham, Esq. Suite 205, 455 East 500 South Salt Lake City, Utah 84111 Re: Sanguine Corporation, a Nevada corporation (the "Company") Dear Mr. Burningham: Thank you for your letter dated December 11, 2001, regarding the...Sanguine Corp • December 17th, 2001 • In vitro & in vivo diagnostic substances
NEITHER THIS WARRANT NOR THE SHARES ISSUABLE ON THE EXERCISE HEREOF HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE AND IS BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE...Sanguine Corp • May 7th, 2002 • In vitro & in vivo diagnostic substances • New York
EXCLUSIVE LICENSE AGREEMENT for Sanguine Corporation Technologies PHER-02 Oxygen-Carrying Synthetic Substitute for Human Red Blood Cells U.S. Patent Pending, Assigned Serial Number 08/230,672 All Derivatives of PHER-02 TABLE OF CONTENTS RECITALS...Exclusive License Agreement • March 25th, 2002 • Sanguine Corp • In vitro & in vivo diagnostic substances • California
INVESTOR RELATIONS/CONSULTING AGREEMENTInvestor Relations/Consulting Agreement • November 28th, 2007 • Sanguine Corp • In vitro & in vivo diagnostic substances • California
This Consulting Agreement ("Agreement"), made and entered into this 4th of April, 2007, by and between Sanguine Corp. (the "Company"), and LKB Partners, LLC. ("Consultant"),
DAVID E. NELSON 528 East 14th Avenue SALT LAKE CITY, UTAH 84103 SANGUINE CORPORATION LOCKUP AGREEMENT Date: June 2, 2000 Sanguine Corporation 101 Green Street, Suite 11 Pasadena, CA 91105 Dear Dr. Drees, The undersigned understands that Sanguine...Sanguine Corp • September 15th, 2000 • In vitro & in vivo diagnostic substances
The undersigned understands that Sanguine Corporation, a Nevada Corporation (the "Company") intends to conduct a private offering of its Common Stock through Laidlaw Global Securities, Inc. ("Laidlaw"). The undersigned recognizes the benefits which the Company will derive from the offering. For and in consideration of the Company's willingness to register the shares of Common Stock, and other consideration, the undersigned hereby agrees as follows:
NOTICE OF TERMINATION WHEREAS, on April 1, 2002, Sanguine Corporation (the "Company" and the "Licensor") entered into an Exclusive License Agreement with Ascendiant-South America, LLC, a Nevada limited liability corporation (the "Licensee"), pursuant...Sanguine Corp • October 7th, 2004 • In vitro & in vivo diagnostic substances
WHEREAS, on April 1, 2002, Sanguine Corporation (the "Company" and the "Licensor") entered into an Exclusive License Agreement with Ascendiant-South America, LLC, a Nevada limited liability corporation (the "Licensee"), pursuant to which the Licensee agreed to certain minimum levels of annual production of the Licensed Products (the "Minimum Production"); and in the event the Licensee failed to achieve the Minimum Production, to pay a royalty to the Licensor; and
LOAN AGREEMENT AND PROMISSORY NOTELoan Agreement and Promissory Note • May 23rd, 2011 • Sanguine Corp • In vitro & in vivo diagnostic substances • Nevada
THIS LOAN AGREEMENT AND PROMISSORY NOTE (the “Note”), is made this 3rd day of January, 2011, by and among Wharton Capital, LLC (hereinafter, known as “LENDER”) and SANGUINE CORP, a Corporation organized under the laws of the State of Nevada (hereinafter, known as “BORROWER”). BORROWER and LENDER shall collectively be known herein as “the Parties”. In determining the rights and duties of the Parties under this Loan Agreement, the entire document must be read as a whole.
SANGUINE CORPORATION 101 East Green Street, Suite 101 Pasadena, California 91105 March 1, 2001 Westbury Consultancy Services Ltd. 8 C Rue Champel Geneve, Suisse Attention: Dr. Luis Copellat Re: Letter of Westbury Consultancy Services Ltd. received...Sanguine Corp • March 7th, 2001 • In vitro & in vivo diagnostic substances
Re: Letter of Westbury Consultancy Services Ltd. received February 27, 2001, respecting the cancellation of the Warrant Agreement, its Addendum and related Warrant dated March 20, 2000, respecting 12,000,000 shares of common stock underlying such Warrant of Sanguine Corporation ("Sanguine")
OPTION AGREEMENTConfidential Option Agreement • November 28th, 2007 • Sanguine Corp • In vitro & in vivo diagnostic substances
THIS OPTION AGREEMENT (this “Agreement”) is entered into as of November 21st, 2007, by and between Thomas C. Drees an individual (the “Seller”), and Terra Silex Holdings LLC, a Pennsylvania LLC (the “Holder”), together with any successors and assigns.
WARRANT AGREEMENT AGREEMENT, dated as of this 13TH day of March, 2000, by and between SANGUINE CORPORATION, a Nevada corporation ("Company"), and Westbury Consultancy Services Limited (the "Warrant Holder"). WITNESSETH: WHEREAS, the Warrant Holder has...Warrant Agreement • October 31st, 2000 • Sanguine Corp • In vitro & in vivo diagnostic substances • Nevada
MANAGEMENT CONSULTING AGREEMENTManagement Consulting Agreement • November 28th, 2007 • Sanguine Corp • In vitro & in vivo diagnostic substances • California
This Consulting Agreement (“Agreement”), made and entered into this 25th of September, 2007, by and between Sanguine Corp. (hereinafter also the “Company” and “SGNC” ), and Thomas C. Drees, Ph.D. (“Consultant”),
CONSULTING AGREEMENTConsulting Agreement • May 20th, 2009 • Sanguine Corp • In vitro & in vivo diagnostic substances • California
THIS AGREEMENT (the “Agreement”) is entered into this 5th day, May, 2009, by and between Sanguine Corp. (hereinafter also “SGUI” or “Party”) with offices located at 6 Green Street, Pasadena, CA and LKB Partners, LLC whose primary offices are located at 3502 Scotts Lane, #1221, Philadelphia, PA (hereinafter also “Consultant” or “Party”) (collectively also “the Parties”),
Stock Option AgreementStock Option Agreement • November 28th, 2007 • Sanguine Corp • In vitro & in vivo diagnostic substances • California
THIS AGREEMENT made as of this 21st day of November, 2007 by and between Thomas C. Drees, an individual of Pasadena, CA (the “Optionor”) and LKB Partners, LLC, of Exton, PA (the “Optionee”).
EMPLOYMENT AGREEMENTEmployment Agreement • February 14th, 2011 • Sanguine Corp • In vitro & in vivo diagnostic substances • Nevada
This AGREEMENT, entered into this 8th day of February, 2011, between Sanguine Corp., a Nevada corporation (the "Company"), and Frank A. Marra (the "Employee"),
Sanguine Corporation 101 East Green Street, Suite 11 Pasadena, California 91105 Attention: The Board of Directors Re: Subscription Agreement to acquire certain shares of common stock that are "restricted securities" of Sanguine Corporation, a Nevada...Sanguine Corp • October 7th, 2004 • In vitro & in vivo diagnostic substances
NOTICE OF TERMINATION WHEREAS, on February 15, 2002, Sanguine Corporation (the "Company" and the "Licensor") entered into an Exclusive License Agreement with Ascendiant-Asia, LLC, a Nevada limited liability corporation (the "Licensee"), pursuant to...Sanguine Corp • October 7th, 2004 • In vitro & in vivo diagnostic substances
WHEREAS, on February 15, 2002, Sanguine Corporation (the "Company" and the "Licensor") entered into an Exclusive License Agreement with Ascendiant-Asia, LLC, a Nevada limited liability corporation (the "Licensee"), pursuant to which the Licensee agreed to certain minimum levels of annual production of the Licensed Products (the "Minimum Production"); and in the event the Licensee failed to achieve the Minimum Production, to pay a royalty to the Licensor; and
SUBSCRIPTION AGREEMENT Dear Subscriber: You (the "Subscriber") hereby agree to purchase, and Sanguine Corporation, a Nevada corporation (the "Company") hereby agrees to issue and to sell to the Subscriber, a 5% Convertible Note convertible in...Subscription Agreement • March 25th, 2002 • Sanguine Corp • In vitro & in vivo diagnostic substances • New York
RESEARCH AND DEVELOPMENT SERVICES AGREEMENT AGREEMENT NUMBER CP036763 LABOR AND MATERIALS TYPE Battelle Memorial Institute, through its Columbus Operations (BATTELLE) agrees to provide to Sanguine Corporation (CLIENT) technical/research services...Research and Development Services Agreement • April 14th, 2000 • Sanguine Corp • In vitro & in vivo diagnostic substances • Ohio
SANGUINE CORPORATION SENIOR CONVERTIBLE PROMISSORY NOTE August 1, 2011Agreement • August 15th, 2011 • Sanguine Corp • In vitro & in vivo diagnostic substances • California
This Agreement (the "Agreement") is made and entered into as of August 1, 2011 (the "Effective Date"), by and between Sanguine Corporation a Nevada corporation ("Borrower"), with a business address of 110 Founders Mill Ct., Roswell, GA 30075 and Wharton Capital LLC, a Delaware limited liability company ("Creditor"), with a business address of 15021 Ventura Blvd. Suite 504, Sherman Oaks, CA 91403. Borrower and Creditor will be referred to throughout the Agreement as "Parties" collectively and "Party" singularly.
FUNDS ESCROW AGREEMENT This Agreement is dated as of the 19 day of March, 2002 among Sanguine Corporation, a Nevada corporation (the "Company"), First York Partners, Inc. ("Subscriber"), and Grushko & Mittman, P.C. (the "Escrow Agent"): W I T N E S S...Funds Escrow Agreement • March 25th, 2002 • Sanguine Corp • In vitro & in vivo diagnostic substances • New York
SANGUINE CORPORATION Up to 10,000,000 Units, Each Unit Consisting of Two Shares of Common Stock and One Redeemable Common Stock Purchase Warrant PLACEMENT AGENCY AGREEMENT May 18, 2000 Laidlaw Global Securities, Inc. 100 Park Avenue New York, New York...Sanguine Corporation • September 15th, 2000 • Sanguine Corp • In vitro & in vivo diagnostic substances • New York
December 11, 2001 Leonard W. Burningham, Esq. Suite 205, 455 East 500 South Salt Lake City, Utah 84111 Re: Sanguine Corporation, a Nevada corporation (the "Company") Dear Mr. Burningham: Thank you for your letter dated December 11, 2001, regarding the...Sanguine Corp • December 17th, 2001 • In vitro & in vivo diagnostic substances
CONSULTING AND CONFIDENTIALITY AGREEMENTConsulting and Confidentiality Agreement • November 28th, 2007 • Sanguine Corp • In vitro & in vivo diagnostic substances
THIS CONSULTING AGREEMENT (hereinafter the “Agreement”), made and entered into this 25th day of October, 2007, by and between KKS Venture Management Inc. and Alfonso Knoll (hereinafter “Consultants”), an independent contractor with a business address of 240 Main Street, Denver PA 17517, and Sanguine Corporation a Nevada corporation (hereinafter “the Company”), (hereinafter together referred to as “the Parties”).
SCS, Inc. letterhead] SANGUINE CORPORATION LOCKUP AGREEMENT Date: June 2, 2000 Sanguine Corporation 101 Green Street, Suite 11 Pasadena, CA 91105 Dear Dr. Drees, The undersigned understands that Sanguine Corporation, a Nevada Corporation (the...Corporation Lockup Agreement • September 15th, 2000 • Sanguine Corp • In vitro & in vivo diagnostic substances
The undersigned understands that Sanguine Corporation, a Nevada Corporation (the "Company") intends to conduct a private offering of its Common Stock through Laidlaw Global Securities, Inc. ("Laidlaw"). The undersigned recognizes the benefits which the Company will derive from the offering. For and in consideration of the Company's willingness to register the shares of Common Stock, and other consideration, the undersigned hereby agrees as follows:
Sanguine Corporation 101 East Green Street, Suite 11 Pasadena, California 91105 Attention: The Board of Directors Re: Subscription Agreement to acquire certain shares of common stock that are "restricted securities" of Sanguine Corporation, a Nevada...Sanguine Corp • October 7th, 2004 • In vitro & in vivo diagnostic substances
Re: Subscription Agreement to acquire certain shares of common stock that are "restricted securities" of Sanguine Corporation, a Nevada corporation (the "Company"), in consideration of the cancellation of certain debt of the Company owed to the undersigned, and the contribution to capital of the Company of certain other debt of the Company to the undersigned
LEONARD W. BURNINGHAM 455 EAST 500 SOUTH, SUITE #205 SALT LAKE CITY, UTAH 84111 SANGUINE CORPORATION LOCKUP AGREEMENT Date: June 2, 2000 Sanguine Corporation 101 Green Street, Suite 11 Pasadena, CA 91105 Dear Dr. Drees, The undersigned understands...Sanguine Corp • September 15th, 2000 • In vitro & in vivo diagnostic substances
The undersigned understands that Sanguine Corporation, a Nevada Corporation (the "Company") intends to conduct a private offering of its Common Stock through Laidlaw Global Securities, Inc. ("Laidlaw"). The undersigned recognizes the benefits which the Company will derive from the offering. For and in consideration of the Company's willingness to register the shares of Common Stock, and other consideration, the undersigned hereby agrees as follows:
STOCK PURCHASE AGREEMENTStock Purchase Agreement • November 28th, 2007 • Sanguine Corp • In vitro & in vivo diagnostic substances
This Stock Purchase Agreement (this “Agreement”) is made and entered into as of September__, 2007 by and among Sanguine Corporation a Nevada corporation (the “Company”), and Terra Silex Holdings LLC, a Pennsylvania LLC (the “Investor”).
MANAGEMENT CONSULTING AGREEMENTManagement Consulting Agreement • November 28th, 2007 • Sanguine Corp • In vitro & in vivo diagnostic substances • California
This Consulting Agreement (“Agreement”), made and entered into this 22 of August, 2007, by and between Sanguine Corp. (hereinafter also the “Company” and “SGNC”), and LKB Partners, LLC. (“Consultant”),
MARKETING AGREEMENTMarketing Agreement • May 15th, 2008 • Sanguine Corp • In vitro & in vivo diagnostic substances • Florida
THIS AGREEMENT made and entered into this 24th day of March 2008, by and between The Cervelle Group, a Delaware LLC, hereinafter referred to as “Cervelle” and Sanguine Corporation, a Nevada corporation hereinafter referred to as "Company".
Chapman Spira & Carson LLC Investment Banking Consultants February 6, 2002 Re: Letter Agreement for Investment Banking Services This letter (the "Letter Agreement") sets forth the arrangements previously discussed whereby Chapman, Spira, & Carson LLC...Sanguine Corp • May 7th, 2002 • In vitro & in vivo diagnostic substances
CONSULTING AGREEMENTConsulting Agreement • May 20th, 2009 • Sanguine Corp • In vitro & in vivo diagnostic substances • California
THIS AGREEMENT (the “Agreement”) is entered into this 28th day, April, 2009, by and between Sanguine Corp. (hereinafter also “SGUI” or “Party”) with offices located at 6 Green Street, Pasadena, CA and Gary Corderman, MBA whose primary offices are located at 15150 Dickens Street, Sherman Oaks, CA (hereinafter also “Consultant” or “Party”) (collectively also “the Parties”),
